Chronic hepatitis C virus infection: a new modifiable cardio-metabolic risk factor?

Tudor Cuciureanu, Stefan Chiriac, Madalina Chiorescu, Irina Gîrleanu, Anca Trifan, Tudor Cuciureanu, Stefan Chiriac, Madalina Chiorescu, Irina Gîrleanu, Anca Trifan

Abstract

Chronic hepatitis C infection is a systemic disease that leads to a high risk of cirrhosis and hepatic carcinoma, as well as extrahepatic related disorders, immune-related and metabolic alterations such as glucose metabolism impairment and steatosis, thus being a new cardio-metabolic risk factor. It has been shown that, due to chronic inflammation, HCV infection has a direct effect on the arterial wall, initiating endothelial dysfunction which is the first step in atherosclerotic processes with proatherogenic effects and numerous cardiovascular events. The recent data emphasize that HCV infection can induce insulin resistance in the liver and peripheral tissues through multiple mechanisms which interfere with insulin signaling, inducing the production of several proinflammatory cytokines, and modify the lipid metabolism with the result of hepatic steatosis, which is more pronounced in patients with HCV. The emergence of new direct acting, interferon-free antiviral treatment, leading to HCV cure in most cases with a satisfactory safety profile is, according to numerous studies, improving the glucose metabolism disorders and lowering the number of cardiovascular events in patients who obtained sustained viral response, thiugh further studies are needed to clarify definitively the role of HCV infection in cardiovascular and metabolic alterations, as well as the impact of viral eradication on cardiovascular outcomes.

Keywords: cardiometabolic risk; hepatitis C virus; insulin resistance.

Figures

Figure 1
Figure 1
Pathogenic pathways of HCV in atherosclerosis.

References

    1. Ampuero J, Romero-Gómez M. Assessing cardiovascular risk in hepatitis C: An unmet need. World J Hepatol. 2015;7:2214–2219.
    1. Bedimo R, Abodunde O. Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients. Curr HIV/AIDS Rep. 2016;13:328–339.
    1. Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxì A, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology. 2016;150:145–155.e4. doi: 10.1053/j.gastro.2015.09.007. quiz e15–6.
    1. Barone M, Viggiani MT, Amoruso A, Schiraldi S, Zito A, Devito F, et al. Endothelial dysfunction correlates with liver fibrosis in chronic HCV infection. Gastroenterol Res Pract. 2015;2015:682174. doi: 10.1155/2015/682174.
    1. Juonala M, Viikari JS, Laitinen T, Marniemi J, Helenius H, Rönnemaa T, et al. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young Finns study. Circulation. 2004;110:2918–2923.
    1. Shaked I, Hanna DB, Gleißner C, Marsh B, Plants J, Tracy D, et al. Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection. Arterioscler Thromb Vasc Biol. 2014;34:1085–1092.
    1. Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med. 2014;5:927–946.
    1. Dai CY, Yeh ML, Huang CF, Hou CH, Hsieh MY, Huang JF, et al. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. J Gastroenterol Hepatol. 2015;30:879–884.
    1. Sillesen H, Muntendam P, Adourian A, Entrekin R, Garcia M, Falk E, et al. Carotid plaque burden as a measure of subclinical atherosclerosis: comparison with other tests for subclinical arterial disease in the High Risk Plaque BioImage study. JACC Cardiovasc Imaging. 2012;5:681–689.
    1. Bos D, Ikram MA, Elias-Smale SE, Krestin GP, Hofman A, Witteman JC, et al. Calcification in major vessel beds relates to vascular brain disease. Arterioscler Thromb Vasc Biol. 2011;31:2331–2337.
    1. Lind L. Flow-mediated vasodilation over five years in the general elderly population and its relation to cardiovascular risk factors. Atherosclerosis. 2014;237:666–670.
    1. Bruno RM, Bianchini E, Faita F, Taddei S, Ghiadoni L. Intima media thickness, pulse wave velocity, and flow mediated dilation. Cardiovasc Ultrasound. 2014 Aug 23;12:34.
    1. Petta S, Torres D, Fazio G, Cammà C, Cabibi D, Di Marco V, et al. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology. 2012;55:1317–1323.
    1. Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis. 2012;221:496–502.
    1. Boddi M, Abbate R, Chellini B, Giusti B, Solazzo V, Soft F, et al. HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. Dig Liver Dis. 2007;39( Suppl 1):S55–S60.
    1. Ishizaka Y, Ishizaka N, Takahashi E, Unuma T, Tooda E, Hashimoto H, et al. Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J. 2003;67:26–30.
    1. Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014;61(1 Suppl):S69–S78.
    1. Cojocaru IM, Cojocaru M, Iacob SA, Burcin C. Cerebral ischemic attack secondary to hepatitis C virus infection. Rom J Intern Med. 2005;43:255–260.
    1. Fuckar K, Lakusic N, Mahovic D, Hirs I. Recurrent strokes as a leading presentation of chronic hepatitis C infection. Arch Med Res. 2008;39:358–359.
    1. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. 1994;21:1135–1139.
    1. Lee MH, Yang HI, Wang CH, Jen CL, Yeh SH, Liu CJ, et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke. 2010;41:2894–2900.
    1. Wong RJ, Gish RG. Metabolic manifestations and complications associated with chronic hepatitis C virus infection. Gastroenterol Hepatol (N Y) 2016;12:293–299.
    1. Schaefer EA, Chung RT. HCV and host lipids: an intimate connection. Semin Liver Dis. 2013;33:358–368.
    1. Butt AA, Yan P, Simon TG, Chung RT, Abou-Samra AB ERCHIVES study team. Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES. BMC Infect Dis. 2015 Nov 11;15:510. doi: 10.1186/s12879-015-1268-2.
    1. Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59:1293–1302.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren